Navigation path

Additional tools

    Profile of registrant

Novo Nordisk

Identification number in the register: 29570313329-11
Registration date: 13/03/2010 10:09:51

The information on this entity was last modified on: 04/02/2015 11:21:34
The date of the last annual update was: 04/02/2015 11:21:34
Next update due latest on: 04/02/2016

    Registrant : Organisation or self-employed individual

Novo Nordisk


    Section of registration

II - In-house lobbyists and trade/business/professional associations

Companies & groups

    Contact details

Novo Allé, 1
Bagsværd 2880

(+45) 44448888

    Person with legal responsibility

Mr  Lars Rebien Sørensen


    Person in charge of EU relations

Mr  Morten Frank Pedersen

Executive Director

    Goals / remit

Novo Nordisk is a global healthcare company with over 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.

Headquartered in Denmark, Novo Nordisk employs approximately 40000 employees in 75 countries. It markets products and services that make a significant difference to patients, the medical profession and society in 190 countries.

Novo Nordisk is committed to developing its business towards environmental, social and financial sustainability (the triple bottom line). This commitment is demonstrated through its values and its environmental and social responsibility policies.

The Novo Nordisk Foundation is a non-profit institution, whose formal purpose is to provide a stable basis for its company's operations and to make contributions to scientific, humanitarian and social progress.

Novo A/S is an unlisted Danish public limited liability company, owned by the Novo Nordisk Foundation and established to manage the Foundation's funds and to invest actively in other companies.

All A and B shares in Novo Nordisk A/S, previously held by the Novo Nordisk Foundation, were transferred to Novo A/S on 31 December 1999. Novo Nordisk’s B shares are listed on the NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).


    Specific activities covered by the Register

EMA Roadmap 2015-2020
EC Study on off-label use of medicines
Medical Devices Regulation
EC Study on environmental risks of medicinal products
General Data Protection Regulation
Transparency Directive
Shareholder Rights Directive
CCCTB Commission Proposal







Novo Nordisk's goals with its involvement with EU institutions are:

- to improve conditions for prevention, treatment and care in Europe to address unmet needs

- to support the voice of people living with or at risk of
developing diabetes

- to increase Europe´s competitiveness as a location for Research and Development

    Number of persons involved in the activities described in the box above

50%: 2   25%: 2



    Persons accredited for access to European Parliament premises

First name Surname Start Date End Date
Ane Sofie Böhm NIELSEN 23/09/2014 19/09/2015

    Fields of interest

  • Competition
  • Enterprise
  • Environment
  • Internal Market
  • Public Health
  • Research and Technology
  • Taxation
  • Trade

    Membership and affiliation

Novo Nordisk is member of:

EFPIA - European Federation of Pharmaceutical Industries and Associations

EBE - European Biopharmaceutical Enterprises

EuropaBio - European Association for Bioindustries

Danish Chamber of Commerce


CSR Europe

    Financial data

01/2014  -  12/2014

50,000 € - 99,999 €

No funding received from the EU institutions during the last closed financial year.

    Code of conduct

By its registration the organisation has signed the Transparency Register Code of Conduct.

The organisation has also declared to be bound to the following other Code:
All EFPIA Codes The Novo Nordisk Way ( Novo Nordisk Business Ethics Policy (